Published in Arthritis Rheum on February 01, 2005
Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther (2006) 1.82
Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther (2006) 1.42
A perspective on B-cell-targeting therapy for SLE. Mod Rheumatol (2009) 1.03
Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med (2003) 4.47
Alternative and classical NF-kappa B signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. Immunity (2006) 2.33
Apoptotic cells with oxidation-specific epitopes are immunogenic and proinflammatory. J Exp Med (2004) 2.10
WASp-deficient B cells play a critical, cell-intrinsic role in triggering autoimmunity. J Exp Med (2011) 1.91
Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. Mol Med (2008) 1.82
Death by a B cell superantigen: In vivo VH-targeted apoptotic supraclonal B cell deletion by a Staphylococcal Toxin. J Exp Med (2003) 1.72
Endosomal TLR signaling is required for anti-nucleic acid and rheumatoid factor autoantibodies in lupus. Proc Natl Acad Sci U S A (2009) 1.70
IgM antibodies to apoptosis-associated determinants recruit C1q and enhance dendritic cell phagocytosis of apoptotic cells. J Immunol (2009) 1.62
Natural antibodies and the autoimmunity of atherosclerosis. Springer Semin Immunopathol (2005) 1.55
Protective Roles of Natural IgM Antibodies. Front Immunol (2012) 1.48
Regulation of dendritic cells and macrophages by an anti-apoptotic cell natural antibody that suppresses TLR responses and inhibits inflammatory arthritis. J Immunol (2009) 1.39
Pathogenic natural antibodies recognizing annexin IV are required to develop intestinal ischemia-reperfusion injury. J Immunol (2009) 1.38
The autoreactivity of anti-phosphorylcholine antibodies for atherosclerosis-associated neo-antigens and apoptotic cells. J Immunol (2003) 1.36
Staphylococcal toxin induced preferential and prolonged in vivo deletion of innate-like B lymphocytes. Proc Natl Acad Sci U S A (2004) 1.25
IgM autoantibodies to distinct apoptosis-associated antigens correlate with protection from cardiovascular events and renal disease in patients with SLE. Clin Immunol (2012) 1.23
Natural IgM in immune equilibrium and harnessing their therapeutic potential. J Immunol (2012) 1.23
Blocking the alpha 4 integrin-paxillin interaction selectively impairs mononuclear leukocyte recruitment to an inflammatory site. J Clin Invest (2006) 1.20
Mucosal plasma cell repertoire during HIV-1 infection. J Immunol (2002) 1.16
Staphylococcus aureus protein A binding to von Willebrand factor A1 domain is mediated by conserved IgG binding regions. FEBS J (2006) 1.13
Prevention and reversal of nephritis in MRL/lpr mice with a single injection of C-reactive protein. Arthritis Rheum (2006) 1.08
Natural IgM: beneficial autoantibodies for the control of inflammatory and autoimmune disease. J Clin Immunol (2014) 1.01
Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment. Arthritis Rheum (2011) 1.01
Natural antibody to apoptotic cell membranes inhibits the proinflammatory properties of lupus autoantibody immune complexes. Arthritis Rheum (2012) 0.93
Cutting Edge: Bim is required for superantigen-mediated B cell death. J Immunol (2007) 0.92
B cell superantigens: a microbe's answer to innate-like B cells and natural antibodies. Springer Semin Immunopathol (2005) 0.90
Fundamental roles of the innate-like repertoire of natural antibodies in immune homeostasis. Front Immunol (2013) 0.89
MAPK phosphatase-1 is required for regulatory natural autoantibody-mediated inhibition of TLR responses. Proc Natl Acad Sci U S A (2012) 0.89
Quantitation of DNA and RNA. CSH Protoc (2007) 0.89
In vivo VL-targeted activation-induced apoptotic supraclonal deletion by a microbial B cell toxin. J Immunol (2004) 0.86
Co-opting endogenous immunoglobulin for the regulation of inflammation and osteoclastogenesis in humans and mice. Arthritis Rheum (2011) 0.85
Bacterial cell wall-expressed protein A triggers supraclonal B-cell responses upon in vivo infection with Staphylococcus aureus. Microbes Infect (2005) 0.84
A recombinant antibody increases cardiac contractility by mimicking phospholamban phosphorylation. FASEB J (2004) 0.84
Naturally occurring autoantibodies to apoptotic cells. Adv Exp Med Biol (2012) 0.83
Temporal and dose-dependent relationships between in vivo B cell receptor-targeted proliferation and deletion-induced by a microbial B cell toxin. J Immunol (2006) 0.82
Rethinking the red wolf disease: does Protein S suppress systemic lupus erythematosus clinical activity? Arthritis Res Ther (2010) 0.78
In vivo VL-targeted microbial superantigen induced global shifts in the B cell repertoire. J Immunol (2012) 0.78
Development of anti-CD20 therapy for multiple sclerosis. Exp Cell Res (2011) 0.77
Efficacy and Safety of Tabalumab, an Anti-B-Cell-Activating Factor Monoclonal Antibody, in a Heterogeneous Rheumatoid Arthritis Population: Results From a Randomized, Placebo-Controlled, Phase 3 Trial (FLEX-O). J Clin Rheumatol (2015) 0.75
Analysis of Programmed Death-1 in Patients with Psoriatic Arthritis. Inflammation (2015) 0.75
Phage-display methodology for the study of protein-protein interactions: overview. CSH Protoc (2008) 0.75
Phage-display methodology for the study of protein-protein interactions: stage 2, panning. CSH Protoc (2008) 0.75
Phage-display methodology for the study of protein-protein interactions: stage 3, binding analysis. CSH Protoc (2008) 0.75
Phage-display methodology for the study of protein-protein interactions: stage 1, generating libraries. CSH Protoc (2008) 0.75
Erratum to: Analysis of Programmed Death-1 in Patients with Psoriatic Arthritis. Inflammation (2015) 0.75
Development of functional human monoclonal single-chain variable fragment antibody against HIV-1 from human cervical B cells. Hybrid Hybridomics (2003) 0.75